# Adenoviral vector gene therapy Replication-defective adenoviral vectors that deliver vaccine antigens and therapeutic genes at industrial scale — platform families validated in pandemic trials, suspension bioreactors to 2,000 L, and the plasmid-to-vector GMP chain that feeds them. The table carries four vendors whose dossier ledgers carry full source trails. Source: https://en.bioecon.ru/technology/adenoviral-vector-gene-therapy/ Updated: 2026-09-18 ## Overview and value chain Markers: [EC: EU ATMP Regulation (EC) No 1394/2007 | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] An adenoviral vector is a stripped-down virus that has lost its replication machinery and gained one job: carry a foreign gene into a cell, let the cell express it, and stand down. The biology that makes this work is also what makes it manufacturable at industrial scale — adenoviruses grow to high titers in suspension cell culture, so a vector campaign runs in bioreactors measured in hundreds to thousands of litres rather than in adherent-cell stacks. The platform logic compounds: one capsid backbone, re-targeted by swapping the expression cassette, serves a vaccine against one pathogen, a vaccine against another, and a gene-therapy indication after that — which is why the same CDMO suites that filled pandemic-dose orders now run clinical ATMP campaigns against them. The chain only works because its least glamorous link, GMP plasmid DNA, industrialized alongside the vectors themselves: a dedicated commercial plasmid facility of 6,400 m² now backs a 16,000 L GMP capacity that has carried more than 140 IND clearances. The corpus's ledger evidence tracks the scale the field reached: a European pure-play CDMO fills up to 3,500 vials per batch from 2,000 L bioreactors behind six GMP suites of 3,470 m², and a Chinese vaccine pioneer that helped prove the platform at population scale reports annual revenue of RMB 1,059.4 million with filling lines on three continents. Key directions of adenoviral vector gene therapy: 1. **Replication-deficient platform families (Ad5 and GRAd):** one validated capsid backbone, many expression cassettes — CanSino Biologics built its position as a global pioneer of adenoviral-vector vaccines on the Ad5 platform, while ReiThera's GRAd lineage descends from the Okairos team that GSK acquired in 2014. 2. **Suspension-scale vector GMP (2,000 L Bioreactors):** high-titer adenoviral production runs in single-use suspension bioreactors up to 2,000 L, with six independent GMP suites (3,470 m²) in Rome keeping campaigns isolated from each other. 3. **Integrated plasmid-to-vector supply (GMP Plasmid Chain):** vectors inherit their quality from their plasmid inputs — a dedicated 6,400 m² commercial GMP plasmid facility in Zhenjiang feeds a 16,000 L GMP capacity with 140+ IND clearances globally as of 2025. 4. **Commercial vector manufacturing at population scale (100-Million-Dose Plants):** CanSino operates production sites in Tianjin and Shanghai with additional lines in Mexico, Pakistan and Malaysia, and a Shanghai facility sized for 100 million doses per year. ### Sectoral value chain ``` [GMP plasmid DNA] ──> [producer cell bank] ──> [bioreactor production] │ (vector titer & identity) │ ▼ [released vector lot] <── [fill-finish] <── [harvest, purification] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Plasmid GMP** | master plasmid bank under GMP | **In:** sequence design. **Out:** GMP plasmid DNA lots. | | **Producer cell bank** | suspension line qualified for infection | **In:** research cell bank. **Out:** GMP-qualified producer cells. | | **Vector production** | high-titer suspension bioprocess | **In:** plasmid, producer cells, 2,000 L bioreactors. **Out:** crude vector harvest. | | **Purification** | chromatography and filtration | **In:** crude harvest. **Out:** vector drug substance. | | **Fill-finish** | low-loss vial filling | **In:** drug substance. **Out:** up to 3,500 vials per batch. | | **Clinical supply** | ATMP-regulated distribution | **In:** released lots. **Out:** FDA/EMA/NMPA-regulated trial and commercial supply. | Cross-cutting technologies of the sector: - **GMP plasmid DNA manufacturing (Plasmid Facilities):** the upstream feedstock of every vector campaign, now industrialized in dedicated 6,400 m² plants. - **Suspension single-use bioreactors (High-Titer Culture):** the scaling backbone that moved adenoviral production off adherent cells. - **Multi-modal vector families (GRAd/MVA/AAV):** CDMO suites that run adenoviral, poxviral and AAV vectors under one quality system. --- ## US The US anchors the regulatory reference framework and one leg of the global manufacturing footprint — vector programs file FDA pathways even when their biology was proven elsewhere. ### FDA frameworks, New Jersey GMP capacity, platform validation lineage - **GenScript ProBio's US site (Hopewell, New Jersey):** the group's GMP footprint spans Nanjing and Zhenjiang in China and Hopewell in the USA, giving US-facing vector and plasmid programs a domestic manufacturing leg with FDA-compliant GMP. - **FDA compliance as table stakes:** GenScript ProBio's certification set spans FDA, EMA, NMPA, PMDA and MFDS — the five-framework posture a global vector CDMO now needs. - **Platform lineage through GSK:** the Okairos founding team that built ReiThera did so after GSK's 2014 acquisition of Okairos, and validated its ChAd/GRAd adenoviral platforms with GSK and in large COVID-19 vaccine trials — a US-headlined validation history behind a European manufacturer. --- ## CN China industrialized adenoviral vectors earliest at population scale and now couples that vaccine base to a fast-growing cell-and-gene-therapy CDMO layer. ### Ad5 vaccine pioneer, STAR-Market CDMO, integrated plasmid capacity - **CanSino Biologics (Tianjin/Shanghai):** a global pioneer of adenoviral-vector vaccines, reporting RMB 1,059.4 million revenue, GMP certificates from Malaysian NAPRA and Halal certification in Indonesia for its Menhycia vaccine, with production lines in Mexico, Pakistan and Malaysia and a Shanghai facility sized for 100 million doses per year. - **OBiO Technology (Shanghai):** SSE STAR Market-listed CRO/CDMO (688238) packaging plasmid, AAV, lentiviral and adenoviral vectors from research grade through GMP Phase I–III to commercial supply, holding a Category C drug manufacturing licence and reporting a fully commercial closed loop in July 2026. - **GenScript ProBio (Nanjing/Zhenjiang):** the ProBio segment revenue of US$388.7 million within a US$959.5 million group rests on 16,000 L of GMP capacity and a dedicated commercial GMP plasmid facility of 6,400 m² in Zhenjiang. --- ## EU Europe contributes the ATMP regulatory framework and the dedicated vector pure-play that grew out of the Okairos lineage. ### EMA ATMP framework, Rome GMP pure-play, poxviral and AAV adjacency - **ReiThera (Rome):** founded 2014 by the Okairos founding team; GMP development and manufacture of adenoviral (GRAd), MVA and AAV vectors for genetic vaccines and advanced therapies in six independent GMP suites totalling 3,470 m². - **Batch economics of vector fill-finish:** up to 2,000 L bioreactor capacity and 3,500 vials per batch on one site — the scale at which a clinical ATMP campaign becomes a routine manufacturing event. - **EMA as second regulator:** vectors validated with GSK and in large COVID-19 vaccine trials file under the ATMP framework the EU pioneered, with EMA compliance part of the five-framework posture global CDMOs carry. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **CanSino Biologics** | 🇨🇳 China | *Ad5 adenoviral-vector vaccine platform* | Adenoviral-vector vaccine pioneer; RMB 1,059.4 m revenue; lines in Mexico, Pakistan, Malaysia; 100 m doses/yr Shanghai facility | Commercial | | **ReiThera** | 🇮🇹 Italy | *GRAd/MVA/AAV vector CDMO* | Okairos lineage; 6 GMP suites, 3,470 m²; 2,000 L bioreactors; 3,500 vials/batch | Commercial | | **OBiO Technology** | 🇨🇳 China | *Plasmid-to-vector CRO/CDMO* | SSE STAR 688238; adenovirus, AAV, lentivirus GMP Phase I–III to commercial; Category C licence; commercial closed loop 2026 | Commercial | | **GenScript ProBio** | 🇨🇳 China | *GMP plasmid and vector supply* | 16,000 L GMP capacity; 6,400 m² plasmid facility; 140+ IND clearances; $388.7 m ProBio revenue | Commercial | --- ## Tech stack and innovations The stack is a quality cascade — plasmid into cell bank into bioreactor into vial — and its innovations are mostly about keeping each link inside one quality system. 1. **High-titer suspension vector production (2,000 L Scale):** - adenoviral vectors replicate to high titers in suspension culture, replacing adherent-cell factories with single-use bioreactors. - case: ReiThera's Rome site runs up to 2,000 L bioreactor capacity with six isolated GMP suites for clinical-grade ATMP production. 2. **Integrated plasmid-to-vector GMP chain (Feedstock Quality):** - vector quality is inherited from plasmid quality; dedicated commercial plasmid plants close the loop between sequence and vector. - case: GenScript ProBio's 6,400 m² Zhenjiang plasmid facility feeding 16,000 L GMP capacity behind 140+ IND clearances and 60+ ongoing CMC projects. 3. **Multi-country commercial packaging (Three-Continent Fill Lines):** - population-scale vaccination demands filling lines close to the markets they serve, under certificates each market accepts. - case: CanSino's lines in Mexico, Pakistan and Malaysia carry GMP certificates from Malaysian NAPRA and Halal certification in Indonesia for the Menhycia vaccine. --- ## Value chains and production pipelines ### Industrial pipeline of an adenoviral vector campaign (EU ATMP GMP regime) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Plasmid GMP │ ───> │ 2. Producer cell bank │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Purification │ <─── │ 3. Bioreactor production │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Fill-finish │ ───> │ 6. Release and supply │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Plasmid GMP The expression cassette arrives as GMP-grade plasmid DNA from a dedicated facility — at 6,400 m², Zhenjiang's plant is sized to feed vector campaigns as a commodity input rather than a bottleneck. #### Stage 2: Producer cell bank A suspension producer line is expanded and qualified under GMP, giving the bioreactor stage a consistent infection substrate. #### Stage 3: Bioreactor production Cells are infected at scale in single-use bioreactors up to 2,000 L; adenoviral replication to high titers is the economics of the whole field. #### Stage 4: Purification Harvest is clarified and purified by chromatography and filtration to vector drug substance, with identity and titer confirmed against the platform reference. #### Stage 5: Fill-finish Drug substance is formulated and filled — up to 3,500 vials per batch on ReiThera's Rome line — under the low-loss aseptic regime clinical ATMP supply requires. #### Stage 6: Release and multi-region supply Released lots ship under FDA, EMA and NMPA compliance; CanSino's Malaysia NAPRA certificate and Indonesia Halal certification show the market-by-market certificate stack commercial vector supply now carries.